Unique ID issued by UMIN | UMIN000039919 |
---|---|
Receipt number | R000045508 |
Scientific Title | Vascular responses to COMBO stent for acute coronary syndrome by Optical Coherence Tomography Assessment |
Date of disclosure of the study information | 2020/03/24 |
Last modified on | 2020/03/24 12:58:14 |
Vascular responses to COMBO stent for acute coronary syndrome by Optical Coherence Tomography Assessment
Vascular responses to COMBO stent for acute coronary syndrome by Optical Coherence Tomography Assessment
Vascular responses to COMBO stent for acute coronary syndrome by Optical Coherence Tomography Assessment
Vascular responses to COMBO stent for acute coronary syndrome by Optical Coherence Tomography Assessment
Japan |
The patients with acute coronary syndrome
Cardiology |
Others
NO
The aim of this study is to elucidate the early phase vascular responses in patients with acute coronary syndrome (ACS) after COMBO stent implantation at 1 month follow-up by using optical coherence tomography (OCT).
Efficacy
The primary endpoint was that the degree of strut coverage which was evaluated by OCT at 1 month. Percentage of strut coverage was analyzed every 1 mm by OCT.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
NO
NO
1
Treatment
Device,equipment |
All patients underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) by using Combo stent.All patients were evaluated by Optical Coherence Tomography (OCT) immediately after stent implantation and were performed OCT follow-up after 1 month.
20 | years-old | <= |
95 | years-old | >= |
Male and Female
1) The patients with ACS need for PCI.
2) Target lesions are thought native coronary arteries.
3) The patients are possible to take antiplatelet drugs.
4) The patients or legal representative people agree this study and write informed consents after they understand this study protocol.
1) The patients with low ejection fraction (less than 20%).
2) The patients with recurrent myocardial infarction within 30 days.
3) The patients with fresh bleeding.
4) The patients with cerebral infarction within 6 months.
5) The patients with hemoglobin < 8.0 g/dl.
6) The patients with WBC <3000 or PLT < 100000.
7) The patients with positive HBV or HCV or HIV.
8) The patients with participate other clinical trial.
9, 10) The patients with pregnant women (including possible) or lactating women
11) The patients with renal failure (Cre>2.5 mg/dl)
12) The patients that research director judged inappropriate patients in this study.
30
1st name | Shigeru |
Middle name | |
Last name | Saito |
ShonanKamakura General Hospital
Cardiology
247-8533
1370-1, Okamoto, Kamakura City
0467-46-1717
transradial@kamakuraheart.org
1st name | Koki |
Middle name | |
Last name | Shishido |
ShonanKamakura General Hospital
Cardiology
247-8533
1370-1, Okamoto, Kamakura City
0467-46-1717
koki10192002@yahoo.co.jp
ShonanKamakura general Hospital, Cardiology
none
Other
The Tokushukai Group Ethics Committee
1-8-7 Kojimachi, Chiyoda-ku, Tokyo, Japan
03-3263-4801
mirai-ec1@mirai-iryo.com
NO
2020 | Year | 03 | Month | 24 | Day |
Unpublished
Open public recruiting
2020 | Year | 03 | Month | 10 | Day |
2020 | Year | 03 | Month | 10 | Day |
2020 | Year | 03 | Month | 12 | Day |
2021 | Year | 12 | Month | 30 | Day |
2020 | Year | 03 | Month | 24 | Day |
2020 | Year | 03 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045508